Adjuvant endocrine therapy for postmenopausal women with early breast cancer

James N. Ingle, Eric Winer, Aman Buzdar, Mitch Dowsett, Myles Brown, Stephen Johnston, Kathleen Pritchard

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor - positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume12
Issue number3 II
DOIs
StatePublished - Feb 1 2006

Fingerprint

Tamoxifen
Breast Neoplasms
Aromatase Inhibitors
letrozole
exemestane
Therapeutics
Colorectal Neoplasms
Knowledge Bases
Progesterone Receptors
Disease-Free Survival
anastrozole
Breast
Placebos
Maintenance
Clinical Trials
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ingle, J. N., Winer, E., Buzdar, A., Dowsett, M., Brown, M., Johnston, S., & Pritchard, K. (2006). Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clinical Cancer Research, 12(3 II). https://doi.org/10.1158/1078-0432.CCR-05-2122

Adjuvant endocrine therapy for postmenopausal women with early breast cancer. / Ingle, James N.; Winer, Eric; Buzdar, Aman; Dowsett, Mitch; Brown, Myles; Johnston, Stephen; Pritchard, Kathleen.

In: Clinical Cancer Research, Vol. 12, No. 3 II, 01.02.2006.

Research output: Contribution to journalArticle

Ingle, JN, Winer, E, Buzdar, A, Dowsett, M, Brown, M, Johnston, S & Pritchard, K 2006, 'Adjuvant endocrine therapy for postmenopausal women with early breast cancer', Clinical Cancer Research, vol. 12, no. 3 II. https://doi.org/10.1158/1078-0432.CCR-05-2122
Ingle, James N. ; Winer, Eric ; Buzdar, Aman ; Dowsett, Mitch ; Brown, Myles ; Johnston, Stephen ; Pritchard, Kathleen. / Adjuvant endocrine therapy for postmenopausal women with early breast cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 3 II.
@article{a7f1517a592347fc882abaed10bb647a,
title = "Adjuvant endocrine therapy for postmenopausal women with early breast cancer",
abstract = "Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor - positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors.",
author = "Ingle, {James N.} and Eric Winer and Aman Buzdar and Mitch Dowsett and Myles Brown and Stephen Johnston and Kathleen Pritchard",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-05-2122",
language = "English (US)",
volume = "12",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3 II",

}

TY - JOUR

T1 - Adjuvant endocrine therapy for postmenopausal women with early breast cancer

AU - Ingle, James N.

AU - Winer, Eric

AU - Buzdar, Aman

AU - Dowsett, Mitch

AU - Brown, Myles

AU - Johnston, Stephen

AU - Pritchard, Kathleen

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor - positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors.

AB - Results from multiple clinical trials involving aromatase inhibitors have added to the knowledge base relating to endocrine therapy of postmenopausal women with hormone receptor - positive early breast cancer. In the extended adjuvant setting, data from the Austrian Breast and Colorectal Cancer Study Group 6a trial showed an advantage for anastrozole following 5 years of tamoxifen treatment, consistent with the more robust MA.17 trial that examined letrozole versus placebo following 5 years of tamoxifen treatment. The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastrozole over continuing the tamoxifen to complete the full 5 years of adjuvant therapy. These trials support the previously reported larger and double-blind Intergroup Exemestane Study. The Arimidex, Tamoxifen, Alone or in Combination trial now has data out to 68 months of median follow-up showing the maintenance of a significant advantage of anastrozole over tamoxifen for disease-free survival. In this initial treatment setting, the Breast International Group 1-98 trial recently showed a significant advantage for letrozole over tamoxifen. The current debate is centered on whether the optimal strategy is to give an aromatase inhibitor initially or after several years of tamoxifen treatment. Multiple important questions remain, including the predictive value of molecular markers such as progesterone receptor, the optimal duration of aromatase inhibitor therapy, the long-term adverse effects, and the relative efficacy and toxicity of the different aromatase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=32944466882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944466882&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2122

DO - 10.1158/1078-0432.CCR-05-2122

M3 - Article

VL - 12

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3 II

ER -